Related Experiment Video
Updated: Jun 28, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Interleukin 6 Signalling in Heart Failure With Preserved and Reduced Ejection Fraction
E V Samoilova1, A А Korotaeva1, I V Zhirov1
1Chazov National Medical Research Center of Cardiology, Moscow.
Insights
Interleukin-6 (IL-6) signaling pathways differ between heart failure types. Understanding these inflammation pathways in chronic heart failure (CHF) may lead to new treatments.
Area of Science:
- Cardiology
- Immunology
- Biochemistry
Background:
- Chronic heart failure (CHF) involves complex inflammatory processes.
- Interleukin-6 (IL-6) plays a critical role in inflammation and cardiac remodeling.
- IL-6 exerts its effects through distinct classical and trans-signaling pathways.
Purpose of the Study:
- To identify and compare the IL-6 signaling pathways in patients with different types of CHF.
- To investigate the differential expression of IL-6 and its receptors in acute decompensated heart failure (ADHF).
Main Methods:
- The study enrolled 164 patients with ADHF: 129 with heart failure with reduced ejection fraction (HFrEF) and 35 with heart failure with preserved ejection fraction (HFpEF).
- Blood levels of IL-6, soluble IL-6 receptor (sIL-6R), soluble gp130 (sgp130), and high-sensitivity C-reactive protein (hsCRP) were measured.
- Correlations between these markers were analyzed in HFrEF and HFpEF groups.
Main Results:
- HFpEF patients exhibited lower IL-6 and hsCRP levels but higher sIL-6R levels compared to HFrEF patients.
- Significant positive correlations between IL-6 and hsCRP, IL-6 and sIL-6R, and IL-6 and sgp130 were observed in HFrEF.
- In HFpEF, a stronger correlation was found only between IL-6 and hsCRP.
Conclusions:
- Classical and trans-signaling pathways of IL-6 are differentially expressed in HFrEF and HFpEF during ADHF.
- These findings enhance understanding of inflammation's role in CHF pathogenesis.
- The results may inform the development of novel therapeutic strategies for CHF.
Aim:
Identification of interleukin-6 (IL-6) signaling pathways in patients with chronic heart failure (CHF).
Material And Methods:
The diversity of IL-6 effects is due to the presence of classical signaling and trans-signaling pathways. The study included 164 patients with CHF hospitalized for acute decompensated heart failure (ADHF), of which 129 had reduced left ventricular ejection fraction (HFrEF), and 35 had preserved ejection fraction (HFpEF). Blood concentrations of IL-6, soluble IL-6 receptor (sIL-6R), soluble transducer protein gp130 (sgp130), and high-sensitivity C-reactive protein (hsCRP) were measured.
Results:
Patients with HFpEF had lower concentrations of IL-6 (6.15 [2.78, 10.65] pg/ml) and hsCRP (11.27 [5.84, 24.40] mg/ml) than patients with HFrEF (9.20 [4.70; 15.62] pg/ml and 17.23 [8.70; 34.51 mg/ml], respectively). In contrast, concentrations of rIL-6R were higher in HFpEF (59.06 [40.00; 75.85] ng/ml) than in HFrEF (49.15 [38.20; 64.89] ng/ml). Concentrations of sgp130 were not significantly different. In patients with HFrEF, positive correlations were found between the concentrations of IL-6 and hsCRP, IL-6 and rIL-6R, and IL-6 and sgp130, while in patients with HFpEF, there was a correlation only between IL-6 and hsCRP, which appeared stronger than in patients with HFrEF (r=0.698; p<0.001 and r=0.297; p<0.05, respectively).
Conclusion:
Classical IL-6 signaling and trans-signaling are expressed to different degrees in patients with HFrEF and HFpEF in ADHF. The results of the study supplement the existing knowledge about the pathogenesis of inflammation in CHF and may contribute to the development of new methods and approaches to the treatment of the disease.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
The JAK-STAT Signaling Pathway
Heart Failure Drugs: Inotropic Agents

